Overview
BNTX market data
Price History
BNTX price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for BNTX. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen FortschrittGlobenewswire Inc · Jul 21, 2026, 11:15 AM
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026Globenewswire Inc · Jul 21, 2026, 11:15 AM
Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their AffiliatesBenzinga · Jul 16, 2026, 11:39 AM
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 13, 2026, 5:15 PM
Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $119Benzinga · Jul 8, 2026, 4:40 PM
'BioNTech Investor Förtsch Says Founders' Spinout Raises Concerns' - Bloomberg NewsBenzinga · Jun 17, 2026, 4:25 PM
UBS Upgrades BioNTech to Buy, Raises Price Target to $135Benzinga · May 27, 2026, 6:15 PM
Bernstein Initiates Coverage On BioNTech with Market Perform Rating, Announces Price Target of $96Benzinga · May 22, 2026, 1:50 PM
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual MeetingGlobenewswire Inc · May 22, 2026, 11:00 AM